Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000548861 | SCV000636927 | uncertain significance | Dilated cardiomyopathy 1AA; Primary familial hypertrophic cardiomyopathy | 2023-06-21 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs758358941, gnomAD 0.006%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 394 of the ACTN2 protein (p.Arg394Gln). This variant has not been reported in the literature in individuals affected with ACTN2-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ACTN2 protein function. ClinVar contains an entry for this variant (Variation ID: 463188). |
CHEO Genetics Diagnostic Laboratory, |
RCV000768735 | SCV000900105 | uncertain significance | Cardiomyopathy | 2016-07-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004992331 | SCV005551711 | uncertain significance | Cardiovascular phenotype | 2024-08-05 | criteria provided, single submitter | clinical testing | The c.1181G>A (p.R394Q) alteration is located in exon 11 (coding exon 11) of the ACTN2 gene. This alteration results from a G to A substitution at nucleotide position 1181, causing the arginine (R) at amino acid position 394 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |